Ernexa Therapeutics Inc. Proceeds from Lines of Credit
Ernexa Therapeutics Inc. (ERNA) reported Proceeds from Lines of Credit of $9.69 million for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-22.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromLinesOfCredit · last filed 2019-03-22
- Ernexa Therapeutics Inc. proceeds from lines of credit for fiscal 2018 was $9.69M, a 900.00% increase from fiscal 2017.
- Ernexa Therapeutics Inc. proceeds from lines of credit for fiscal 2017 was $969.00K, a 0.00% change from fiscal 2016.
- Ernexa Therapeutics Inc. proceeds from lines of credit for fiscal 2016 was $969.00K, a 89.45% decline from fiscal 2015.
- Ernexa Therapeutics Inc. proceeds from lines of credit for fiscal 2015 was $9.19M.
| Period end | Proceeds from Lines of Credit 12 month |
|---|---|
| 2018-12-31 | $9.69M 10-K · filed 2019-03-22 |
| 2017-12-31 | $969.00K 10-K · filed 2018-03-09 |
| 2016-12-31 | $969.00K 10-K · filed 2017-03-09 |
| 2015-12-31 | $9.19M 10-K · filed 2016-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |